PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.15%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-30.87%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.35%
Operating expenses reduction while Biotechnology median is 7.38%. Seth Klarman would investigate advantages.
-30.35%
Total costs reduction while Biotechnology median is 7.96%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-2.47%
D&A reduction while Biotechnology median is 0.31%. Seth Klarman would investigate efficiency.
30.79%
EBITDA growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
30.35%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-41.49%
Other expenses reduction while Biotechnology median is -4.37%. Seth Klarman would investigate advantages.
30.26%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% versus flat Biotechnology. Walter Schloss would verify strategy.
30.26%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
30.58%
EPS change of 30.58% versus flat Biotechnology. Walter Schloss would verify quality.
33.88%
Diluted EPS change of 33.88% versus flat Biotechnology. Walter Schloss would verify quality.
0.94%
Share count reduction below 50% of Biotechnology median of 0.04%. Jim Chanos would check for issues.
5.92%
Diluted share reduction below 50% of Biotechnology median of 0.02%. Jim Chanos would check for issues.